Every material Form 8-K MANNKIND CORP has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MannKind reported third quarter 2026 total revenues of $101.9 million, up 24% from a year earlier, mainly due to Furoscix, acquired from scPharma in October 2025. The company posted a net loss of $23.2 million, or $0.07 per share, compared with net income of $8.0 million, or $0.03 per share, in the prior-year quarter, as selling, general and administrative expenses rose to $61.4 million. For shareholders, revenue growth came with higher costs and a loss, and the company reported $96.6 million in cash, cash equivalents and investments as of September 30, 2026.
Total revenues were $101.9 million, up from $82.1 million in Q3 2025; Furoscix contributed $22.4 million.
Net loss was $23.2 million ($0.07 per share), compared with net income of $8.0 million ($0.03 per share) a year earlier.
Selling, general and administrative expenses were $61.4 million, up 111% from $29.1 million; commercial cost of goods sold was $11.2 million vs. $4.5 million.
Furoscix ReadyFlow shipments began in mid-September, and about 75% of weekly Furoscix shipments had transitioned to ReadyFlow by late October.
MannKind filed a prospectus supplement to its automatic shelf registration statement on Form S-3 on August 21, 2026, covering the issuance and sale of its common stock. The filing attaches a legal opinion from Cooley LLP on the legality of those share issuances. The filing does not state the size of the offering, the price, or the proceeds.
Prospectus supplement filed August 21, 2026 under Form S-3 Registration No. 333-285286
Exhibit 5.1 is the Cooley LLP opinion on the legality of the common stock issuance
Filing does not state the number of shares, offering price, or proceeds
MannKind reported second quarter 2026 total revenues of $109.4 million, up 43% from $76.5 million a year earlier, driven by the Furoscix acquisition and higher collaborations and royalties. The company posted a net loss of $19.0 million, or $0.06 per share, compared with net income of $668 thousand a year earlier, as operating expenses rose sharply, including selling, general and administrative expenses of $58.3 million.
Q2 2026 total revenues of $109.4 million, up 43% from $76.5 million in Q2 2025
Net loss of $19.0 million, or $0.06 per share, versus net income of $668 thousand, or $0.00 per share, in Q2 2025
Furoscix net sales of $22.2 million and Afrezza net sales of $17.0 million in Q2 2026
Cash, cash equivalents and investments totaled $111 million as of June 30, 2026; a $50 million private placement closed July 24, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MANNKIND CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →